首页> 美国卫生研究院文献>Aging (Albany NY) >Pyrrolo 34-b-quinolin-9-amine compound FZU-0038-056 suppresses triple-negative breast cancer partially through inhibiting the expression of Bcl-2
【2h】

Pyrrolo 34-b-quinolin-9-amine compound FZU-0038-056 suppresses triple-negative breast cancer partially through inhibiting the expression of Bcl-2

机译:吡咯咯34-b-喹啉-9-胺化合物FZU-0038-056通过抑制Bcl-2的表达部分抑制三阴性乳腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Triple-negative breast cancer (TNBC) has a poorer prognosis than other subtypes of breast cancer; however, it lacks effective targeted therapies clinically. In this study, we found FZU-0038-056, a novel compound derived from last-stage functionalization of tetrahydro-β-carboline scaffold, showed the most potent anti-cancer activity against TNBC cells among the 42 synthesized derivatives. We found FZU-0038-056 significantly induces apoptosis in HCC1806 and HCC1937 TNBC cells. FZU-0038-056 reduces the expression levels of several anti-apoptosis proteins, including Bcl-2, Mcl-1 and XIAP. Furthermore, we found FZU-0038-056 induces apoptosis partially through inhibiting the expression of Bcl-2. Finally, we found FZU-0038-056 significantly suppresses HCC1806 xenograft tumor growth in nude mice without affecting their body weight. Therefore, FZU-0038-056 has the potential to be a new anticancer agent for treating human TNBC.
机译:三阴性乳腺癌(TNBC)的预后要比其他亚型的乳腺癌差。但是,它在临床上缺乏有效的靶向疗法。在这项研究中,我们发现FZU-0038-056是一种从四氢-β-咔啉骨架的最后阶段官能化衍生的新型化合物,在42种合成衍生物中显示出对TNBC细胞最有效的抗癌活性。我们发现FZU-0038-056显着诱导HCC1806和HCC1937 TNBC细胞凋亡。 FZU-0038-056降低了几种抗凋亡蛋白的表达水平,包括Bcl-2,Mcl-1和XIAP。此外,我们发现FZU-0038-056通过抑制Bcl-2的表达部分诱导细胞凋亡。最后,我们发现FZU-0038-056可以显着抑制HCC1806异种移植瘤在裸鼠体内的生长,而不会影响它们的体重。因此,FZU-0038-056有潜力成为治疗人TNBC的新型抗癌药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号